The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
Julius Clinical is proud to announce our continued sponsorship of Bio-Neuroscience 2025, the premier summit for CEOs, investors, and industry decision-makers in CNS neuroscience drug development.Taking place in Amsterdam from 25-27 February 20...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
At Julius Clinical, we are proud to announce the first formal meeting of our Dementia Scientific Advisory Board (SAB) with Prof. Philip Scheltens and Prof. John Harrison—a major milestone in our commitment to advancing dementia research and clin...
"*" indicates required fields
"*" indicates required fields
